Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs TKO Group Holdings Inc (TKO) Price & Performance

BioNano Genomics IncTrade
TKO Group Holdings IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs TKO Group Holdings Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while TKO Group Holdings Inc trades at $187.5 (market cap $13.84B). The key difference: TKO Group Holdings Inc is far larger — about 1048.5× BioNano Genomics Inc's market cap, and TKO Group Holdings Inc pays a 1.69% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BNGOTKO
Market Cap
$13.20M$13.84B
Sector
HealthTechnology
52-Week High
$4.92$224.96
52-Week Low
$1.09$155.61
Enterprise Value
$15.81M$18.01B
Dividend Yield
1.69%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

TKO Group Holdings Inc

TKO Group Holdings trades at $180.96, down 1.87% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported strong Q1 2026 earnings beat but missed Q3 and Q4 2025 expectations. Revenue grew to $4.74B in 2025 with net income of $195.4M, while 2026 projections show continued growth to $5.1B revenue. Recent developments include successful international events and an $800M share repurchase completion.

Wall Street maintains strong bullish sentiment with 89% buy ratings and $228 consensus price target, representing 26% upside. Key risks include execution on earnings guidance and competitive pressures in sports entertainment. The company's premium valuation (P/E 68.6) requires sustained growth delivery, while positive cash flow trends and dividend payments provide shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About TKO Group Holdings Inc

TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.

Read more on TKO